Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment

Study Overview
=================
Brief Summary
-----------------
This study is a 52-weeks, multicenter, randomized, double-blind, double- placebo, parallel controlled phase VI trial being carried out in 20 centers around China. The study population includes amnestic mild cognitive impairment patients (planned a total of 360) aged 55-85 in both gender. Participants will be randomly allocated to Qinggongshoutao bolus (7g per time,2 times per day) and placebo identified to Ginkgo biloba (Ginaton), Ginkgo biloba (Ginaton) (80mg per time, 2 times per day) and placebo identified to Qinggongshoutao bolus, or placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo biloba (Ginaton) for a 52-weeks double-blind treatment period. The primary outcome measure is change from baseline in the Alzheimer's Disease Assessment Scale- Cognition Subscale (ADAS-cog) and rate of conversion to dementia. The secondary outcomes are changes from baseline in the Mini-Mental State Examination(MMSE), Delayed Story Recall(DSR), Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24). Safety is being assessed by observing side effects and adverse reaction during the entire treatment period. Statistical analysis will be conducted according to per-protocol population and intend-to-treat population and the safety will be analyzed in safety set.

Official Title
-----------------
The Efficacy and Safety of Qinggongshoutao Bolus for aMnestic Mild Cognitive Impairment: A 52- Week Randomized, Double-blind, Controlled,Three Arms, Multi-center Study

Conditions
-----------------
Mild Cognitive Impairment, Herbal Medicine Allergy

Intervention / Treatment
-----------------
* Drug: Qinggongshoutao Bolus
* Drug: Ginkgo Biloba Extract 761
* Drug: Placebos


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cognitive complaints from the patients or their families; objective evidence for memory impairment, delayed story recall test(DSR)<12.6(age50-64 less than15.5,65-74less than 12.5,older 75 less than10); normal general cognitive function, with Mini-Mental State Examination (MMSE) score of between 24 and 30 (including 30); preservation of activities of daily living, with Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24) score between 38 and 52; cognitive disorders as evidenced by clinical evaluation, with clinical dementia rating scale=0.5,memory domain = 0.5; absence of dementia, not sufficiently impaired cognitively and functionally to meet DSM-IV criteria, enough vision and hearing to accomplishment neuropsychological test; capability to read words and write simple sentence; capability and willingness to give informed consent and to comply with the study procedures. Exclusion Criteria: non amnestic Mild cognitive impairment; meeting the diagnostic criteria for dementia; cognitive impairment resulting from conditions such as acute cerebral trauma, cerebral damage due to a lack of oxygen, epilepsy vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation, or a brain tumor ,or drug abuse or alcohol abuse having significant psychiatric disease, depression, the Hamilton depression scale >12; CT or MRI scan showed central nervous system infections Infarction or focal lesions within 12 months，the Hachinski Ischemic Scale (HIS)>4; combined following disease: diabetes; poor controlled hypertension or severe arrhythmias; or suffered from heart infarction within 3 months; severe asthma or COPD; severe indigestion; gastrointestinal tract obstruction; gastroduodenal ulcer; used cholinesterase inhibitors or memantine within 1 month; history of hypersensitivity to the treatment drugs; concomitant drugs with the potential to interfere with cognition; administration of other investigational drugs; severe impairment of the functions of the kidney or liver; vegetarians or contraindications for animal innards.

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Qinggongshoutao Bolus<br>Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761 .Qinggongshoutao bolus 70 pills every time (7g), 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks. | Drug: Qinggongshoutao Bolus<br>* Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761<br>* Other names: Ginkgo biloba also named Egb761 or Ginaton;|
| Active Comparator: Ginkgo Biloba Extract 761<br>Ginkgo Biloba Extract 761 and placebo identified to Qinggongshoutao bolus.The subjects will take Ginkgo Biloba Extract 761 2 times per day, 2 pills per time(80mg) ,and identified to Qinggongshoutao bolus 70 pills every time, 2 times per day for 48 weeks. | Drug: Ginkgo Biloba Extract 761<br>* Placebo identified to Qinggongshoutao bolus and Ginkgo Biloba Extract 761<br>* Other names: Ginkgo biloba also named Egb761 or Ginaton;|
| Placebo Comparator: Placebos<br>Placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761.Placebo identified to Qinggongshoutao bolus 70 pills every time, 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks. | Drug: Placebos<br>* Placebo identified to Qinggongshoutao Bolus and placebo identified to Ginkgo biloba<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline to end of double-blind treatment of Alzheimer Disease Assessment Scale-cognitive subscale |  | week 0, week 4, week 12, week 24 ,week 36 , week 48 and week 52. | 
| Change from baseline to end of double-blind treatment of rate of conversion to dementia |  | week 0, week 4, week 12, week 24 ,week 36 , week 48 and week 52. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mini-Mental State Examination(MMSE) |  | week 0, week 4, week 12, week 24 ,week 36 , week 48 and week 52. | 
| Change from baseline to end of double-blind treatment of Delayed Story Recall test (DSR) |  | week 0, week 4, week 12, week 24 ,week 36 , week 48 and week 52. | 
| Change from baseline to end of double-blind treatment of Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24) |  | week 0, week 4, week 12, week 24 ,week 36 , week 48 and week 52. |